Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Marios P. Decatris"'
Publikováno v:
Journal of Clinical Oncology. 34:884-886
Autor:
Ioannis Michaelides, Marios P. Decatris, Nicolaos Nicolaou, Michalis Kounoushis, Nicos Katodritis, Angela Katodritou, Demetris Christou, Panayiotis Hadjicostas
Publikováno v:
Clinical Case Reports
Key Clinical Message Melanomas of the gallbladder (GB) are extremely rare with a very poor prognosis. They feature in the literature as a few case reports and the method of their management is not clear. We report a case of patient with metastatic cu
Autor:
Kenneth J. O'Byrne, Marios P. Decatris
Publikováno v:
Future oncology (London, England). 12(15)
Advanced non-small-cell lung cancer (NSCLC) has a poor prognosis with few treatment options available for patients after failure of first-line therapy. Nivolumab is the first immune checkpoint inhibitor targeting the PD-1 to be approved in recurrent
Autor:
Marios P. Decatris, R. Panchal, M. Chandiramani, Laurence Brown, B. Morgan, C. Joynson, R.P. Symonds
Publikováno v:
Clinical Oncology. 18:641-648
Paraneoplastic syndromes are a collection of disorders affecting an organ or tissue caused by cancer but occurring at a site distant from the primary or metastases. Dermatomyositis can occur in association with malignancy as a paraneoplastic phenomen
Publikováno v:
Clinical Oncology. 17:249-257
Aims After failure of anthracycline- and taxane-based chemotherapy in metastatic breast cancer, treatment options until recently were limited. Until the introduction of capecitabine and vinorelbine, no standard regimen was available. We conducted a r
Publikováno v:
The International Journal of Biological Markers. 19:262-267
Endothelin-1 (ET-1) is a potent vasoactive peptide and a hypoxia-inducible angiogenic growth factor associated with the development and growth of solid tumours. This study evaluated the expression of big endothelin-1 (big ET-1), a stable precursor of
Autor:
Sundar Santhanam, R.A. Sharma, Marios P. Decatris, Ahmed Osman, S. Khanna, Kenneth J. O'Byrne, Rajarshi Roy, Christine B. Clarke
Publikováno v:
Cancer Chemotherapy and Pharmacology. 52:367-370
The development of liver metastases from breast cancer is associated with a very poor prognosis, estimated at 4 months median survival. Since treatment with many chemotherapeutic agents is relatively contraindicated, we assessed the safety, tolerabil
Publikováno v:
BioDrugs. 16:349-372
The second part of this review examines the use of recombinant interferon-alpha (rIFNalpha) in the following solid tumours: superficial bladder cancer, Kaposi's sarcoma, head and neck cancer, gastrointestinal cancers, lung cancer, mesothelioma and ov
Publikováno v:
BioDrugs. 16:261-281
Interferon-α (IFNα) is a pleiotropic cytokine with direct and indirect antitumour effects. These include prolongation of the cell cycle time of malignant cells, inhibition of biosynthetic enzymes and apoptosis, interaction with other cytokines, and
Publikováno v:
The journal of the British Menopause Society. 10(1)
Metastatic breast cancer (MBC) may present de novo but more commonly develops in women initially presenting with early breast cancer despite the widespread use of adjuvant hormonal and cytotoxic chemotherapy. MBC is incurable. Hormone sensitive MBC e